letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...2526272829303132333435...100101»
  • ||||||||||  LOXO-783 / Eli Lilly
    LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models (Hall 1) -  Oct 10, 2022 - Abstract #SABCS2022SABCS_1159;    
    P1
    Results Combining LOXO-783 with either fulvestrant (FUL; CI at 50% inhibition = 0.28) or imlunestrant (CI at 50% inhibition = 0.43) showed increased efficacy in cell proliferation assays using the HR+, HER2-, PI3Kα H1047R- mutant T47D model...Similar results were observed in a T47D model engineered to express ESR1 D538G, as well as in an HR+, HER2- PI3Kα double in-cis mutant model (H1047R/D350G) also harboring ESR1 D538G and derived from a patient who had progressed on prior letrozole plus taselisib...Extending these studies to additional treatment settings, LOXO-783 was similarly efficacious as a single agent in abemaciclib-resistant and abemaciclib/FUL double-resistant models, and was additive in combination with paclitaxel in a triple negative breast cancer model in vitro and in vivo...LOXO-783 is also efficacious in ESR1 mutant as well as in abemaciclib and abemaciclib/FUL double-resistant models. A phase 1 trial of LOXO-783 alone or in combination with anticancer therapies is ongoing (PIKASSO-01; NCT05307705).
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Unusual hepatotoxicity with the use of Ribociclib in a premenopausal patient (Hall 1) -  Oct 10, 2022 - Abstract #SABCS2022SABCS_466;    
    In the case of premenopausal women, the use of ovarian suppression + aromatase inhibitor or tamoxifen associated with ribociclib demonstrated not only a gain in disease-free survival, but also in overall survival, making it the first choice of treatment for premenopausal women with HER2 negative hormone receptor-positive metastatic breast cancer...Her first-line treatment was according to the Monaleesa-7 trial with goserelin 3.6 mg every 28 days + letrozole 2.5 mg daily + ribociclib 600 mg/day for 21 days and a break for 7 days, without delays or dose reductions...It is generally well tolerated, however laboratory monitoring should be performed throughout the treatment period. Hepatotoxicity, although rare, may occur, with improvement after discontinuation of the drug.
  • ||||||||||  letrozole / Generic mfg.
    Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitors letrozole and exemestane in sequence (Stars at Night Ballroom 3&4) -  Oct 10, 2022 - Abstract #SABCS2022SABCS_245;    
    Specifically, we show changes in the proportion of CD8 effector memory cells under treatment pressure, with a significant increase in cytotoxic T cell proportions after two months of treatment with aromatase inhibitor. Conclusions We use single cell profiling to obtain a high-resolution map of the cell types found in tumor biopsies of the NEOLETEXE trial to characterize the effects of aromatase inhibitors on the tumor microenvironment and to identify the cancer cell signatures during treatment with letrozole or exemestane.
  • ||||||||||  letrozole / Generic mfg.
    Estradiol represses anti-tumoral immune response to promote progression of triple-negative breast cancer brain metastases (Hall 3) -  Oct 10, 2022 - Abstract #SABCS2022SABCS_176;    
    Our results support the hypothesis that estradiol promotes brain metastatic progression by stimulating an immunosuppressive brain microenvironment. As such, FDA-approved E2-depletion therapies (aromatase inhibitors and selective-estrogen modulators) could be used in combination with brain irradiation and PD-1 inhibitors to promote a more effective anti-tumoral immune response.
  • ||||||||||  Steroidal and Nonsteroidal Aromatase Inhibitors Induced Dermatitis- A Case Report of Cross-reactivity (Exhibit Hall (Upper Concourse); Monitor 01) -  Oct 10, 2022 - Abstract #ACAAI2022ACAAI_802;    
    There are two major classes: nonsteroidal (Anastrozole and Letrozole) and steroidal (Exemestane)...The medication was stopped with resolution and the patient is now doing well on Tamoxifen...To our knowledge this is the first patient reported in literature to have reacted to both classes of AI. Further studies are required to determine the best alternative agents for such patients.
  • ||||||||||  letrozole / Generic mfg.
    IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer (T253ABC) -  Oct 6, 2022 - Abstract #SITC2022SITC_1452;    
    Finally, tumor-infiltrating γδ T cells increase as compared to baseline in patients relapsing on CDK4/6 inhibitors. Conclusions Our findings prompt the initiation of clinical trials comparing standard-of-care CDK4/6 inhibition plus letrozole vs CDK4/6 inhibition plus letrozole and an IL17 blocker (at least three of which are currently approved for psoriasis treatment) in patients with HR + HER2­ - breast cancer.
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients - immunophenotype results from AWARE-1 study (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_881;    
    P1
    1 Previous data from the window of opportunity AWARE-1 study demonstrated that pela, alone or in combination with atezolizumab (atezo), establishes a favorable immunologic response in tumors from HR+/HER2- early breast cancer (BC) patients...Methods Treatment naïve HR+/HER2- early BC patients were enrolled in two cohorts: Cohort 1 (C1)– pela + letrozole (n=10); and Cohort 2 (C2)– pela + letrozole + atezo (n=10)...Conclusions These data suggest that combining pela with atezo may improve outcomes in HR+/HER2- BC by enhancing the cytotoxic and anti-tumor activity of T cells. Trial Registration NCT04102618
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Oct 4, 2022   
    P1/2,  N=255, Active, not recruiting, 
    Mature oocyte yield was similar across groups. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) -  Oct 4, 2022   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023 Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Sep 2023